Finance

Lists
Outlook: 92.9% bullish·0.0% bearish
Go to analysis
LGND:NASDAQ
Ligand Pharmaceuticals Inc
$322.75
+1.71%
(+5.42) 1D
$324.00
+0.39% (+1.25)
After hours
Closed: Oct 30, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LGND...
Open
$319.22
High
$324.90
Low
$314.50
Mkt. cap
6.43B
Avg. vol.
258.62K
Volume
344.31K
P/E ratio
34.33
52-wk high
$326.63
52-wk low
$175.89
EPS
$9.40
Beta
1.06
Shares outstanding
19.94M
No. of employees
47
Open
$319.22
High
$324.90
Low
$314.50
Mkt. cap
6.43B
Avg. vol.
258.62K
Volume
344.31K
P/E ratio
34.33
52-wk high
$326.63
52-wk low
$175.89
EPS
$9.40
Beta
1.06
Shares outstanding
19.94M
No. of employees
47
News stories
From web sources and news partners
Profile
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
About Ligand Pharmaceuticals Inc
CEO-
Employees47
FoundedSep 1987
HeadquartersJupiter, Florida, United States
SectorPharmaceutical industry
Websiteligand.com
Analyst ratings
Based on 8 analysts giving stock ratings to LGND in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for LGND in the last 3 months.
Highest
Current $322.75
$406.00 (+25.79%)
Average
$365.57 (+13.27%)
Lowest
$345.00 (+6.89%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Zemansky
Bank of America Securities
Buy
Maintained
$406.00
+25.8%
10/30/2026
Leland Gershell
Oppenheimer
Buy
Maintained
$346.00
+7.2%
10/30/2026
Douglas Miehm
RBC Capital
Buy
Reiterated
$357.00
+10.6%
10/29/2026
Annabel Samimy
Stifel Nicolaus
Buy
Reiterated
$350.00
+8.4%
10/30/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$397.00
+23%
10/29/2026
Glen Santangelo
Barclays
Buy
Maintained
$345.00
+6.9%
10/30/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$358.00
+10.9%
10/29/2026
Matt Hewitt
Craig-Hallum
Buy
Reiterated
-
-
09/24/2026
Robert Wasserman
StoneX
Buy
Maintained
$335.00
+3.8%
07/16/2026
Sahil Dhingra
RBC Capital
Buy
Reiterated
$262.00
-18.8%
05/11/2026
Albert Lowe
Craig-Hallum
Buy
Initiated
-
-
04/27/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
115.46M
59.67M
51.72M
63.69M
Cost of goods sold
24.82M
6.50M
5.42M
17.88M
Cost of revenue
24.82M
6.50M
5.42M
17.88M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
28.45M
25.03M
20.84M
29.12M
Operating expense
36.54M
33.12M
28.93M
37.22M
Total operating expenses
61.36M
39.63M
34.35M
55.10M
Operating income
54.10M
20.04M
17.37M
8.59M
Other non operating income
390.00K
1.48M
-1.18M
2.68M
EBT including unusual items
141.14M
56.78M
-24.26M
64.30M
EBT excluding unusual items
57.45M
116.80M
21.10M
52.55M
Income tax expense
23.86M
12.00M
-10.91M
15.80M
Effective tax rate
16.91%
21.13%
44.99%
24.56%
Other operating expenses
-
-
-
-
Net income
117.27M
44.78M
-13.34M
48.51M
Net profit margin
101.57%
75.06%
-25.80%
76.16%
Earnings per share
3.09
2.02
1.63
2.37
Interest and investment income
3.87M
6.39M
6.66M
7.30M
Interest expense
-910.00K
-1.78M
-1.75M
-1.75M
Net interest expenses
2.96M
4.61M
4.91M
5.55M
Depreciation and amortization charges
-
-
-
-
EBITDA
62.37M
28.25M
25.58M
16.81M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps